Key Opinion Leader Breakfast with Dr. Roger Bullock:
Epigenetic Approaches to Neurodegenerative Disorders
Hosted by: Oryzon Genomics
July 25, 2017
The Benjamin Hotel
125 E 50th St, New York,
Presentation starts at 8am
(Registration starts at 7:30am)
Please join Oryzon for a Key Opinion Leader Breakfast. Speaking will be Roger Bullock, MD, Chief Medical Officer of Oryzon Genomics and Carlos Buesa, PhD, Chief Operating Officer of Oryzon Genomics.
Dr. Bullock will be discussing epigenetic approaches to neurodegenerative disorders. Dr. Bullock is considered a world KOL in the space of neurodegenerative diseases. He has extensive experience as clinical researcher, having participated in more than 70 clinical trials in Alzheimer’s disease and other CNS conditions. Over his 30-year research career, he has authored and co-authored more than 100 peer- r reviewed publications and book chapters in this domain and presented at numerous conferences. Recently he has been working as a consultant for companies active in the CNS space, including Lilly and Merck.
A founder of the Company in 2000, he has held the position of Chair of the Board of Directors since then. He earned his Ph.D. in Biochemistry from the University of Barcelona, and has completed various programs on finance and negotiation. He also completed the Senior Management Program (PADE) at IESE in 2005. In recent years, he has been a member of the board of various biotechnology companies: ONCNOSIS PHARMA AIE, NINFAS AIE, ORYCAMB-PROJECT AIE, GEADIG-PHARMA AIE, NEUROTEC PHARMA, S.L., PALOBIOFARMA, S.L. He has been a member of the Advisory Board of NEUROSCIENCES TECHNOLOGIES and is a member of MENDELION, S.L. He is ORYZON’s representative on the Governing Board of the Asociación Española de Bioempresas (ASEBIO), of which ORYZON has been a member since 2005, except for the period between 2009 and 2011, during which ORYZON was appointed as Vice Chair of such Governing Board. The first vice chairmanship of ASEBIO is held by Oryzon since the last elections held in December 2015 and until the next elections, which must be held before the end of 2017. Finally, he has been a member of the Board of Directors of INVEREADY SEED CAPITAL and of INVEREADY BIOTECH since September 7, 2008 and October 10, 2012, respectively.